Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESR1 peptide vaccine in ER+ breast cancer
NCT04270149Phase 1Active, not recruiting
- Sponsor
- Herbert Lyerly
- Start
- Sep 2020
- Primary completion
- May 2025
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of esr1 peptide vaccine in breast cancer, sponsored by Herbert Lyerly. Primary endpoint: Number of Adverse Events at 44 days. Started Sep 2020; status: active, not recruiting.
02
Drugs
esr1 peptide vaccine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04270149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04270149.